IL251813D0 - Combination - Google Patents

Combination

Info

Publication number
IL251813D0
IL251813D0 IL251813A IL25181317A IL251813D0 IL 251813 D0 IL251813 D0 IL 251813D0 IL 251813 A IL251813 A IL 251813A IL 25181317 A IL25181317 A IL 25181317A IL 251813 D0 IL251813 D0 IL 251813D0
Authority
IL
Israel
Prior art keywords
combination
Prior art date
Application number
IL251813A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462068141P priority Critical
Priority to PCT/EP2015/074271 priority patent/WO2016062722A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL251813D0 publication Critical patent/IL251813D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
IL251813A 2014-10-24 2017-04-20 Combination IL251813D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201462068141P true 2014-10-24 2014-10-24
PCT/EP2015/074271 WO2016062722A1 (en) 2014-10-24 2015-10-20 Combination

Publications (1)

Publication Number Publication Date
IL251813D0 true IL251813D0 (en) 2017-06-29

Family

ID=54347516

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251813A IL251813D0 (en) 2014-10-24 2017-04-20 Combination

Country Status (16)

Country Link
US (1) US20190194654A1 (en)
EP (2) EP3550019A1 (en)
JP (1) JP2017537070A (en)
KR (1) KR20170072928A (en)
CN (1) CN107106590A (en)
AU (1) AU2015335029A1 (en)
CA (1) CA2965034A1 (en)
DK (1) DK3209778T3 (en)
ES (1) ES2727154T3 (en)
HU (1) HUE043227T2 (en)
IL (1) IL251813D0 (en)
PL (1) PL3209778T3 (en)
RU (1) RU2017117664A3 (en)
SG (1) SG11201703219WA (en)
TR (1) TR201906415T4 (en)
WO (1) WO2016062722A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027845A2 (en) * 2014-05-29 2017-10-31 Medimmune Llc ox40l fusion proteins and uses thereof
BR112017019559A2 (en) 2015-03-13 2018-05-15 Cytomx Therapeutics Inc anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of using these
BR112017023849A2 (en) 2015-05-07 2018-07-17 Agenus Inc anti-ox40 antibodies and methods of use
AU2016294440A1 (en) 2015-07-13 2018-02-22 Cytomx Therapeutics, Inc. Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3411407A1 (en) 2016-02-05 2018-12-12 Orionis Biosciences NV Bispecific signaling agents and uses thereof
CN109069631A (en) * 2016-04-25 2018-12-21 免疫医疗有限责任公司 The composition of total preparation comprising anti-PD-L1 and anti-CTLA-4 antibody
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US20180021270A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2018089780A1 (en) * 2016-11-11 2018-05-17 Medimmune, Llc Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2019023525A1 (en) * 2017-07-28 2019-01-31 Dana-Farber Cancer Institute, Inc. Enhanced immunotherapy of cancer using targeted transcriptional modulators
WO2019177159A1 (en) * 2018-03-15 2019-09-19 国立大学法人北海道大学 Cancer immunotherapy companion drug
WO2019206987A1 (en) * 2018-04-25 2019-10-31 Medimmune Limited Formulations of human anti-pd-l1 antibodies

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
JPH0525470B2 (en) 1981-10-30 1993-04-13 Nippon Chemiphar Co
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc Modified antibodies.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
DK1877090T3 (en) 2005-05-06 2014-04-14 Providence Health System Trimed ox40-immunoglobulin fusion protein and methods for using it
BRPI0613361A2 (en) 2005-07-01 2011-01-04 Medarex Inc isolated human monoclonal antibody, composition, immunoconjugate, bispecific molecule, isolated nucleic acid molecule, expression vector, host cell, transgenic mouse, method for modulating an immune response in an individual, method for inhibiting tumor cell growth in an individual, method for treating an infectious disease in a subject, a method for enhancing an immune response to an antigen in a subject, a method for treating or preventing an inflammatory disease in a subject, and a method for preparing the anti-pd-11 antibody
US20070243184A1 (en) 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
US7547684B2 (en) 2006-05-11 2009-06-16 Isis Pharmaceuticals, Inc. 5′-modified bicyclic nucleic acid analogs
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008109494A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof
US20100298409A1 (en) 2007-09-17 2010-11-25 Intradigm Corporation Compositions comprising stat3 sirna and methods of use thereof
WO2009089149A1 (en) 2008-01-03 2009-07-16 The Johns Hopkins University B7-h1 (cd274) antagonists induce apoptosis of tumor cells
SI2342226T1 (en) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
CN104479018B (en) 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR101934071B1 (en) 2009-11-24 2019-01-02 메디뮨 리미티드 Targeted binding agents against b7-h1
MY163004A (en) 2011-04-01 2017-07-31 Ionis Pharmaceuticals Inc Modulation of signal transducer and activator of transcription 3 (stat3) expression
RS57324B1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
EP2812022B1 (en) 2012-02-06 2019-06-26 Providence Health & Services - Oregon Method of monitoring cancer treatment using ox40 agonists
US20150157710A1 (en) 2012-03-02 2015-06-11 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Dual ox40 agonist/il-2 cancer therapy methods
CA2866707A1 (en) * 2012-03-07 2013-09-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
NZ706540A (en) 2012-10-31 2018-11-30 Ionis Pharmaceuticals Inc Dosage regimens for treatment of cancer

Also Published As

Publication number Publication date
AU2015335029A1 (en) 2017-05-18
US20190194654A1 (en) 2019-06-27
TR201906415T4 (en) 2019-05-21
KR20170072928A (en) 2017-06-27
RU2017117664A (en) 2018-11-26
PL3209778T3 (en) 2019-08-30
RU2017117664A3 (en) 2019-05-23
CA2965034A1 (en) 2016-04-28
JP2017537070A (en) 2017-12-14
EP3550019A1 (en) 2019-10-09
WO2016062722A8 (en) 2017-03-09
WO2016062722A1 (en) 2016-04-28
EP3209778B1 (en) 2019-04-03
EP3209778A1 (en) 2017-08-30
HUE043227T2 (en) 2019-08-28
ES2727154T3 (en) 2019-10-14
SG11201703219WA (en) 2017-05-30
CN107106590A (en) 2017-08-29
DK3209778T3 (en) 2019-05-27

Similar Documents

Publication Publication Date Title
GB201413019D0 (en) Beyond 1B
HK1217861A1 (en) Wifi-coordinated laa-lte
GB201419865D0 (en) Solution
SG11201703219WA (en) Combination
GB201410907D0 (en) No details
GB201402431D0 (en) Compounds
GB201418300D0 (en) Compounds
GB201419094D0 (en) Anti-TIM-3-antibodies
SG11201605342UA (en) Compounds
GB201404893D0 (en) Selfie - Stick
SI3204377T1 (en) Aminopyridyloxypyrazole compounds
ZA201607951B (en) Diaminotriazine compounds
GB201516146D0 (en) None
AU359704S (en) Case
AU361515S (en) Dishrack
GB201415573D0 (en) Compounds
GB2528557B (en) Soundbar
GB201410430D0 (en) Compounds
GB201413050D0 (en) None
GB201418217D0 (en) No details
GB201418216D0 (en) No details
GB2529896B (en) Multirotor
SI3097397T1 (en) Schienenmesssystem
SG11201606762PA (en) Combination
GB201417561D0 (en) Compounds